CAMBRIDGE, Mass.--(BUSINESS WIRE)--Critical Biologics Corporation (CBC) and Scarab Genomics announced today a strategic agreement to substantially increase the manufacturing yield of CBC’s lead therapeutic protein candidate, Solinex™, an intravenous formulation of recombinant human plasma gelsolin (rhu-pGSN). Solinex™ is in Phase 2 development to determine whether plasma gelsolin replacement therapy can prevent critically ill patients from developing many of the life-threatening complications that appear to be strongly associated with hypogelsolinemia, including acute respiratory distress syndrome (ARDS), severe sepsis syndrome, multiple organ system failure (MOSF) and death.
